AMA Mandates Human Oversight for AI Claim Denials

The fast-moving world of AI in healthcare presents huge opportunities and some serious risks. As these AI tools get plugged into daily clinical work, the need for real oversight and ethical rules is getting urgent. You can see this tension most clearly in how insurers use AI to deny claims, a practice that organized medicine is now watching like a hawk. The American Medical Association (AMA), a major player in healthcare policy, has now put its foot down, adopting a formal policy to deal with AI’s role in these decisions.

The AMA’s Stance: Human Oversight for AI-Assisted Denials

The AMA’s House of Delegates, which speaks for doctors nationwide, has passed a policy that requires a human to actually examine a patient’s records before any AI-assisted denial of care can happen. This policy, which started taking shape in 2023 and was locked in by delegate votes through 2025-2026, is a direct pushback against the murky and potentially dangerous use of AI in prior authorizations. The AMA is also very specific about language, insisting these systems be called “augmented intelligence” to show they are supposed to be tools that support a doctor’s judgment. The policy also demands that insurers using these tools be transparent and accountable. This isn’t just a position paper. It’s a reaction to real-world problems. The resolution that led to this policy pointed directly to a ProPublica investigation on Cigna PxDx, which uncovered that Cigna’s PxDx system allowed its doctors to deny over 300,000 claims in just two months, spending an average of only 1.2 seconds on each case. While this article focuses on the AMA’s policy, it is important to note that this same investigation also contributed to the Cigna PxDx lawsuit, which has been covered on this site. The AMA’s message to the industry is clear: you can’t chase AI efficiency if it comes at the cost of patient care and a doctor’s autonomy.

Physician Concerns Fueling the Policy

The AMA’s new rule reflects what doctors are seeing every day as they fight with automated prior authorization systems. An AMA physician survey from 2026 showed just how bad it’s gotten, with 61% of doctors believing AI is directly causing more prior-authorization denials. The consequences for patients are severe. A full 94% of the surveyed physicians said they’ve seen poor clinical outcomes because of these denials, and 93% reported major delays in getting patients the care they need. These numbers show the real-world damage of letting unguarded AI run loose in healthcare administration. There’s a massive disconnect here: insurers talk about how AI can make things simpler, but doctors are the ones who see it harming patients and blocking access to treatment. The AMA’s requirement for a human review before any denial is an attempt to put a clinical failsafe back into the process and curb the risks of fully automated decisions.

Transparency and Accountability: Core Demands from Organized Medicine

The AMA’s policy does more than just require a human reviewer. It also demands transparency and accountability from insurance companies. This means insurers need to provide straightforward explanations for how their AI algorithms reach a decision and create a real pathway for doctors to challenge those decisions with the full clinical picture. AMA President Willie Underwood III, MD, put it bluntly: “Physicians must be able to appeal decisions and ensure that patient needs are prioritized over algorithmic efficiency.” AMA press release on AI in prior authorization. This speaks to a deep worry in the medical community that secret, proprietary algorithms are just black boxes that spit out arbitrary denials without any good reason or way to fight back. In the same vein, AMA Board Member Marilyn Heine, MD, has been pushing for strong accountability. “The promise of AI in healthcare is immense,” Dr. Heine said, “but its deployment must be accompanied by rigorous ethical guidelines and clear accountability. Patients deserve to know that their care decisions are made by humans, not solely by algorithms.” AMA policy page on augmented intelligence. These comments from AMA leadership show the organization is determined to make AI a helpful tool, not an unaccountable boss. This push for transparency also covers the data used to train the AI, the biases that might be baked into the models, and the systems for checking their performance over time.

Contrasting Unguarded AI with Clinically Validated AI

The AMA policy creates a sharp line between two types of AI: unguarded and clinically validated. Unguarded AI, which the Cigna PxDx situation is a perfect example of, runs with little to no human oversight and is built for speed and cost-cutting. When you use a system like that for something as important as claim denials, you’re asking for trouble, delayed diagnoses, patients not getting the right level of care, and wrong treatments because of red tape. The fact that Cigna’s PxDx system spent an average of 1.2 seconds per case shows exactly how an AI-only process can blow past the kind of clinical details a human reviewer would spot. Clinically validated AI, on the other hand, is what the AMA calls “augmented intelligence,” where the tech helps people do their jobs better. This means the AI has gone through tough clinical validation, its design is transparent, it’s constantly watched for errors, and (most importantly) a human is always in the loop for big decisions. For example, a good AI for prior authorization might automatically flag a case that doesn’t fit standard guidelines, but the final call to deny care would always be made by a qualified doctor who has the patient’s complete medical record in front of them. This is how you prevent AI-driven health misinformation and keep the tech in its place as a support tool. The AMA’s policy makes it obvious that organized medicine backs this augmented intelligence model, especially when a patient’s access to care is on the line. The American Medical Association’s policy against AI-only claim denials is a major move to set ethical and practical rules for AI in healthcare. By insisting on human review, transparency, and accountability, the AMA is trying to protect patients from the dangers of unchecked automation. This stance, built on doctor feedback and real-world incidents, shows that clinical judgment has to come before administrative speed. Investors and policymakers should take this as a direct signal from the medical community about the standards they expect for any AI tool used in our healthcare system.